Early Phase Support for Plasmid DNA Supply Helps Secure Future Manufacturing for Advanced Therapies
Summary: One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell or gene therapies that require pDNA as a starting material. Building a robust supply of GMP-grade pDNA requires that quality be a focal point of the production process. In addition, the integration of process development, manufacturing, packaging, and supply logistics of pDNA are critical to improving access and reducing timelines as this brings life-changing therapies to the patient sooner.
Watch this webinar for an in-depth discussion of the challenges CGT innovators face and how experts resolve these barriers through adopting technologies and strategies that drive an optimized plasmid production process and supply.